Taienkang

Guangdong Taienkang Pharmaceutical is a comprehensive healthcare company based in China, specializing in the R&D, manufacturing, and distribution of pharmaceuticals and medical devices. The company is a market leader in men's health, particularly known for its dominant market share in treatments for premature ejaculation and erectile dysfunction under brands like Wandeli. Following the strategic acquisition of Shandong Boshi Pharmaceutical, Taienkang has expanded its focus toward innovative drug development in dermatology, oncology, and chronic kidney disease. The company operates a dual-business model that combines high-growth internal product manufacturing with an extensive distribution network for international healthcare brands. Listed on the Shenzhen Stock Exchange, Taienkang maintains multiple GMP-certified production facilities and is actively advancing a pipeline of both generic and proprietary small molecule therapies.